Sara Ghaseminejad Kermani

Sara Ghaseminejad Kermani

Auto-generated profile, based on publicly available information

Sara Ghaseminejad Kermani

Department of Emergency Medicine, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in Journal of Nephropharmacology
Verified
Journal Article
Closed access
SBShahriar Barkhordari
Shahriar Barkhordari
SGShahrzad Ghaffariyan
Shahrzad Ghaffariyan
FBFarzin Banei
Farzin Banei
MSMohammad Shirvani
Mohammad Shirvani
FYFarangis Yazdanjou
Farangis Yazdanjou
MMMobin Mohammadtabar
Mobin Mohammadtabar
Introduction: Diabetic retinopathy is one of the principal causes of blindness globally. The impact of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, a category of anti-diabetic medications, on diabetic retinopathy remains undetermined. Consequently, this study aimed to examine the association between the utilization of SGLT2 inhibitors and the incidence of diabetic retinopathy. Materials and Methods: This investigation systematically searched databases, including Web of Science, Cochrane, ProQuest, PubMed, and Google Scholar, until March 7, 2024. A systematic review and meta-analysis methodology was employed. Data were analyzed using STATA software version 14, considering a significance level of tests at P<0.05. Results: The application of SGLT2 inhibitors was connected with a diminished diabetic retinopathy risk (odds ratio [OR]: 0.77, 95% CI: 0.69, 0.86). Among women, SGLT2 inhibitor use did not notably influence diabetic retinopathy risk (OR: 0.84, 95% CI: 0.69, 1.03). However, among men, employing SGLT2 inhibitors decreased the risk (OR: 0.81, 95% CI: 0.71, 0.92). In comparison to dipeptidyl peptidase-4 inhibitors (OR: 0.70, 95% CI: 0.53, 0.94) and pioglitazone (OR: 0.75, 95% CI: 0.74, 0.76), SGLT2 inhibitors lowered the risk of diabetic retinopathy. However, when compared to sulfonylureas (OR: 0.45, 95% CI: 0.17, 1.17) and GLP1-RA (OR: 0.70, 95% CI: 0.42, 1.17), SGLT2 inhibitors did not notably affect diabetic retinopathy. Moreover, using SGLT2 inhibitors in the age groups of 50-54 years (OR: 0.74, 95% CI: 0.55, 0.98), 55-59 years (OR: 0.65, 95% CI: 0.53, 0.79), and 60-64 years (OR: 0.89, 95% CI: 0.82, 0.97) was linked to lower diabetic retinopathy risk. Nevertheless, in the 65-69 age group, SGLT2 inhibitor administration did not significantly alter the diabetic retinopathy risk (OR: 1.04, 95% CI: 0.94, 1.15). Conclusion: The intake of SGLT2 inhibitors has been linked to a diminution in the hazard of diabetic retinopathy. However, further research in this domain is recommended, given the need for studies examined. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42024523959) and Research Registry (UIN: reviewregistry1808) website.

2 November 2024 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
HMHossein Mardanparvar
Hossein Mardanparvar
HMHediyeh Mesbahi
Hediyeh Mesbahi
SRSara Rasta
Sara Rasta
RARasoul Jafari Arismani
Rasoul Jafari Arismani
SKSara Ghaseminejad Kermani
Sara Ghaseminejad Kermani
MRMahin Roozitalab
Mahin Roozitalab
Introduction: The study is motivated by the growing concern surrounding chronic kidney disease worldwide and the need for early identification and effective management to slow or prevent kidney disease progression. To achieve this goal, we evaluated the correlation between body mass index (BMI) and estimated glomerular filtration rate (eGFR) in patients with IgA nephropathy through a systematic review and meta-analysis. Materials and Methods: The data were acquired after conducting a comprehensive exploration of the international databases of PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine until June 2024. The study heterogeneity was evaluated utilizing the I2 index. The data were scrutinized employing STATA 14, and a P value < 0.05 was considered significant. Results: Seven studies with a sample size of 1354 normal BMI people and 1020 obese or overweight patients were included in this meta-analysis. Based on the findings of the weighted mean difference (WMD), individuals who are overweight or obese had a lower eGFR (WMD = -7.34 [CI; -9.62, -5.05], P<0.001). Conclusion: The results demonstrated that the eGFR was significantly lower in obese or overweight people compared to individuals with normal BMI; therefore, we conclude that being overweight or obese may hurt kidney function. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023417633) and Research Registry (UIN: reviewregistry1665) websites.

4 November 2025 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
MFMaryam Farajisani
Maryam Farajisani
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
ZMZahra Hamidi Madani
Zahra Hamidi Madani
ZZZeinab Zamanpour
Zeinab Zamanpour
HRHamid Rastad
Hamid Rastad
FDForoohar Darabi
Foroohar Darabi
Introduction: Gestational diabetes mellitus (GDM) is a common metabolic disorder during pregnancy, and the triglyceride-glucose (TyG) index is among the indicators that can predict the occurrence of gestational diabetes. Accordingly, our goal was to examine the relationship between the TyG index and GDM. Materials and Methods: Databases of Scopus, PubMed, Embase, Web of Science, Cochrane, and Google Scholar search engine were used for articles published until September 5, 2025. Data was analyzed using STATA 14. Tests with P values<0.05 were considered statistically significant. Results: High TyG index in general (OR:1.77, 95% CI: 1.56, 2), in the second one-third (OR:1.90, 95% CI: 1.08, 3.36), third one-third (OR:3.94, 95% CI: 2.07, 7.50), second quartile (OR:1.24, 95% CI: 1.07, 1.44), third quartile (OR:1.58, 95% CI: 1.28, 1.94), fourth quartile (OR:2.42, 95% CI: 1.85, 3.17), second quantile (OR:1.23, 95% CI: 1.05, 1.43), third quantile (OR:1.44, 95% CI: 1.23, 1.68), fourth quantile (OR:2.15, 95% CI: 1.41, 3.28), fifth quantile (OR:2.92, 95% CI: 1.96, 4.37) increased the risk of GDM. Furthermore, high TyG index levels increased the risk of GDM in China (OR:1.84, 95% CI: 1.59, 2.13), Korea (OR:1.43, 95% CI: 1.08, 1.89), cohort studies (OR:1.82, 95% CI: 1.60, 2.07), women groups with mean ages ≥ 35 (OR:2.54, 95% CI: 1.84, 3.51), and women with BMIs ≥ 25 (OR:2.56, 95% CI: 2.06, 3.18). Conclusion: High TyG index levels increased the risk of GDM by about 77%, and higher TyG index levels led to even higher possibilities of GDM occurrence. Additionally, obese and overweight women and those aged ≥ 35 were more exposed to this disease than other women. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251143086) and Research Registry (UIN: reviewregistry2046) websites.

9 November 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
RAR.J. Arismani
R.J. Arismani
MMM. Miri
M. Miri
SKS.G. Kermani
S.G. Kermani
MNM.S.Q. Nou
M.S.Q. Nou
MSM. Safari
M. Safari
Introduction: Kidney transplantation is a critical treatment for end-stage kidney disease, but its costs vary widely across countries and over time. Objectives: This study investigates changes in kidney transplantation costs between 2019 and 2023 using data from the International Society of Nephrology Global Kidney Health Atlas (ISN-GKHA). Methods: This ecological study analyzed kidney transplantation costs reported globally for 2019 and 2023 using data from the ISN-GKHA. The study included countries with complete cost data for both years, excluding those with missing or inconsistent records. Data collection focused on extracting first-year and subsequent annual transplantation costs from the publicly available ISN database. The primary outcome was the change in transplantation costs over time, evaluated to identify trends and regional variations in expenses across the included countries. Results: The trend from 2019 to 2023 in kidney transplantation costs varies by continent and globally. In Latin America, Brazil showed the highest increase, while Bolivia had the smallest. Oceania and Southeast Asia saw Australia with the largest increase and Indonesia with a decrease. Western Europe had the Netherlands with the greatest rise and Germany with a decrease. Saudi Arabia had the highest increase in the Middle East, while the West Bank and Gaza had the least. South Asia’s Bangladesh showed a modest increase. In North America, the United States experienced the largest increase, whereas Canada had a decrease. North and East Asia saw Japan with the most notable increase and China with a decrease. Africa had Morocco with the highest increase and Egypt with the smallest. Eastern and Central Europe recorded the largest rise in Slovenia and the smallest in Serbia. Overall, the United States had the most significant increase, while Germany showed the greatest decrease. Conclusion: The findings highlight significant regional disparities in kidney transplantation costs globally, emphasizing the necessity for targeted healthcare policies and ongoing monitoring to ensure cost-effective and equitable access to transplantation services worldwide.

17 August 2025 in Journal of Nephropharmacology
Verified
Journal Article
Open access
PDF file
SASajad Ataei Azimi
Sajad Ataei Azimi
AKAsaad Abass Fadhel Khalif
Asaad Abass Fadhel Khalif
ASAhmadreza Siyasari
Ahmadreza Siyasari
ZBZahra Bazargani
Zahra Bazargani
PKPeyman Khajehnabi
Peyman Khajehnabi
SSShirin Shamsghahfarokhi
Shirin Shamsghahfarokhi
Chronic kidney disease (CKD) is a global health burden, often complicated by anemia due to impaired erythropoietin production and iron dysregulation. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has emerged as a promising therapeutic option for managing anemia in CKD patients. By stabilizing hypoxia-inducible factors, vadadustat enhances endogenous erythropoietin production and improves iron metabolism, offering a novel approach to treating CKD-associated anemia. Recent clinical trials demonstrate that vadadustat effectively increases hemoglobin levels, reduces the need for erythropoiesis-stimulating agents (ESAs), and improves patients’ quality of life. However, concerns regarding its safety, including potential risks of thromboembolic events and hypertension, warrant careful patient selection and monitoring. Comparative analyses with standard therapies, such as ESAs and other HIF-PH inhibitors, highlight vadadustat’s advantages in terms of oral administration and cost-effectiveness, while also identifying areas for further research.

16 November 2024 in Journal of Preventive Epidemiology
Verified
Journal Article
Open access
PDF file
SKSara Ghaseminejad Kermani
Sara Ghaseminejad Kermani
JRJalal Rezaei
Jalal Rezaei
SRSara Rasta
Sara Rasta
MAMeysam Arbuzia
Meysam Arbuzia
TBTayabeh Bahmani
Tayabeh Bahmani
HMHossein Mardanparvar
Hossein Mardanparvar
Lipoprotein (a) is a type of lipoprotein that consists of a cholesterol-rich low-density lipoprotein particle bound to a unique protein called apolipoprotein (a). A strengthened risk of vascular diseases, such as stroke and coronary artery disease is accompanied by elevated levels of this protein. However, recent research has also highlighted the potential role of lipoprotein (a) in kidney-related conditions. Lp (a) appears to play a significant role in kidney diseases. An increased risk of kidney disease development and progression, diabetic nephropathy and renal artery stenosis, and renal transplant dysfunction accompanies high plasma values of Lp (a).